KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. ET. A live webcast will be available on their website, with an audio archive accessible for 30 days post-event. KalVista focuses on developing oral protease inhibitors for unmet medical needs, particularly targeting hereditary angioedema and diabetic macular edema. Their candidates include KVD900, KVD824, and KVD001, currently in various clinical trial phases.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the 21^st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:00 p.m. ET.

A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentations.

About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks and has initiated the Phase 3 KONFIDENT clinical trial. KVD824 is in development for prophylactic treatment of HAE, with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information about KalVista, please visit www.kalvista.com.

Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including the potential impact of COVID-19, that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT and Phase 2 KOMPLETE clinical trials, and to obtain regulatory approvals for KVD900, KVD824 and other candidates in development, the ability of KVD900, KVD824 and other candidates in development to treat HAE or DME, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2021, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005126/en/

KalVista Pharmaceuticals, Inc.

Ben Palleiko

CBO & CFO

857-999-0890

investors@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

When is KalVista Pharmaceuticals presenting at the Needham Virtual Healthcare Conference?

KalVista Pharmaceuticals will present on April 13, 2022, at 3:00 p.m. ET.

Where can I watch the KalVista Pharmaceuticals conference presentation?

You can watch the live webcast of the presentation on KalVista's website.

What are the key drug candidates being developed by KalVista Pharmaceuticals?

KalVista is developing KVD900 for acute hereditary angioedema attacks, KVD824 for prophylactic treatment, and KVD001 for diabetic macular edema.

What is the status of KalVista’s clinical trials?

KalVista is conducting the Phase 3 KONFIDENT trial for KVD900 and the Phase 2 KOMPLETE trial for KVD824.

What therapies does KalVista Pharmaceuticals focus on?

KalVista focuses on oral protease inhibitors for hereditary angioedema and diabetic macular edema.